
    
      This is a multicenter, open-label, single-arm, phase 4, estimation study in adults with
      plaque psoriasis (PsO) who have failed apremilast. The study will consist of a screening
      period of up to 45 days, a 24-week treatment period with study visits every 4 weeks, and a
      30-day follow-up period for safety. Etanercept dosing will follow the recommended label
      dosing for adults with plaque psoriasis.
    
  